Citation Impact
Citing Papers
CD4+ Count–Guided Interruption of Antiretroviral Treatment
2006 Standout
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Discovery and optimization of nonpeptide HIV-1 protease inhibitors
1996
Rapid Diversity‐Oriented Synthesis in Microtiter Plates for In Situ Screening of HIV Protease Inhibitors
2003
Resistance of HIV Type 1 to Proteinase Inhibitor Ro 31-8959
1995
Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, x-ray crystallography, and infected T-cell assays
1992
Peptidomimetics derived from natural products
1993
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
1997 Standout
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
1997 Standout
Tuberculosis in Patients with Human Immunodeficiency Virus Infection
1999 Standout
UCSF Chimera—A visualization system for exploratory research and analysis
2004 Standout
Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine
1995
Predicting Drug‐Resistant Mutations of HIV Protease
2007 StandoutNobel
Novel nonpeptidic inhibitors of HIV-1 protease obtained via a new multicomponent chemistry strategy
2004
Structure of a G48H mutant of HIV‐1 protease explains how glycine‐48 replacements produce mutants resistant to inhibitor drugs1
1997
A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection
1995
HIV Drug Resistance
2004
HIV as the cause of AIDS
1996 StandoutNobel
A Catalytic Asymmetric 6 π Electrocyclization: Enantioselective Synthesis of 2‐Pyrazolines
2009 StandoutNobel
Computer Aided Drug Design: Success and Limitations
2016
Inhibitors of HIV‐1 Protease by Using In Situ Click Chemistry
2006 StandoutNobel
Structure at 2.5-.ANG. resolution of chemically synthesized Human Immunodeficiency Virus Type 1 protease complexed with a hydroxyethylene-based inhibitor
1991
Asymmetric 1,3-Dipolar Cycloaddition Reactions
1998 Standout
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
2013 Standout
Design, Activity, and 2.8 Å Crystal Structure of a C 2 Symmetric Inhibitor Complexed to HIV-1 Protease
1990 Science
Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design
1997 Standout
Bioorganometallic Chemistry of Ferrocene
2004 Standout
Progress in the Discovery of Biosynthetic Anticancer Drugs
1996
Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future [published erratum appears in Blood 1991 Dec 15;78(12):3330]
1991
HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
1996 StandoutScience
Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials
2004
HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
1995 StandoutScience
Molecular Targets for AIDS Therapy
1990 Science
Sequential Allylic C–H Amination/Vinylic C–H Arylation: A Strategy for Unnatural Amino Acid Synthesis from α-Olefins
2012
Peptidomimetics—Tailored Enzyme Inhibitors
1994
Water as an Active Constituent in Cell Biology
2007 Standout
Design, structure activity and x-ray crystallographic studies of pseudosymmetrical nonpeptidyl HIV-1 protease inhibitors
1994
Development of a Large-Scale Process for an HIV Protease Inhibitor
1997
Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1.
1994 StandoutNobel
State of the Art and Prospects in Metal–Organic Framework (MOF)-Based and MOF-Derived Nanocatalysis
2019 Standout
Engineered Biosynthesis of β‐Alkyl Tryptophan Analogues
2018 StandoutNobel
Asymmetric Dipolar Cycloadditions of Me3SiCHN2. Synthesis of a Novel Class of Amino Acids: Azaprolines
1997
Crystal Structure at 3.5 Å Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor
1992 StandoutScience
Multiple Mutations in the Human Immunodeficiency Virus Protease Gene Are Responsible for Decreased Susceptibility to Protease Inhibitors
1995
The Hitchhiker’s Guide to Flow Chemistry
2017 Standout
Engineering enzymes for noncanonical amino acid synthesis
2018 StandoutNobel
X=Y=ZH Systems as potential 1,3-dipoles. Part 58: Cycloaddition route to chiral conformationally constrained (R)-pro-(S)-pro peptidomimetics
2003
The Organocatalytic Approach to Enantiopure 2H‐ and 3H‐Pyrroles: Inhibitors of the Hedgehog Signaling Pathway
2016 StandoutNobel
New dipeptide isosteres useful for the inhibition of HIV-1 protease
1994
Synthesis and biological evaluation of a series of HIV-1 protease inhibitors
1993
Crystal structures of HIV-1 protease-inhibitor complexes
1993
Total Synthesis of α-Pyrone Meroterpenoids, Novel Bioactive Microbial Metabolites
2005 StandoutNobel
Implicit Solvation Models: Equilibria, Structure, Spectra, and Dynamics
1999 Standout
Structure of a Covalently Trapped Catalytic Complex of HIV-1 Reverse Transcriptase: Implications for Drug Resistance
1998 StandoutScience
Recent Developments in Isocyanide Based Multicomponent Reactions in Applied Chemistry
2005 Standout
A Formal [3 + 3] Cycloaddition Approach to Natural‐Product Synthesis
2004
Bis Tertiary Amide Inhibitors of the HIV-1 Protease Generated via Protein Structure-Based Iterative Design
1996
Simple and Versatile Synthesis of Optically Active 1,2‐Amino Alcohols by Grignard Addition toN,O‐Dibenzylglyceraldimine and ‐lactaldimine
1994
Positive Effects of Combined Antiretroviral Therapy on CD4 + T Cell Homeostasis and Function in Advanced HIV Disease
1997 StandoutScience
Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450
1996
Structure-Based Design of β-Site APP Cleaving Enzyme 1 (BACE1) Inhibitors for the Treatment of Alzheimer’s Disease
2013
The Unenlarged Lymph Nodes of HIV-1–infected, Asymptomatic Patients with High CD4 T Cell Counts Are Sites for Virus Replication and CD4 T Cell Proliferation. The Impact of Highly Active Antiretroviral Therapy
1998 StandoutNobel
Transition-Metal-Catalyzed C−S, C−Se, and C−Te Bond Formation via Cross-Coupling and Atom-Economic Addition Reactions
2011 Standout
Pathogenesis of human immunodeficiency virus infection
1993
Computationally designed peptide macrocycle inhibitors of New Delhi metallo-β-lactamase 1
2021 StandoutNobel
Structure-Based Strategies for Drug Design and Discovery
1992 Science
A Field Guide to Foldamers
2001 Standout
Additions of Organometallic Reagents to CN Bonds: Reactivity and Selectivity
1998 Standout
ITERATIVE PROTEIN STRUCTURE-BASED DRUG DESIGN AND SYNTHESIS OF HIV PROTEASE INHIBITORS
1995
Pt nanoparticles entrapped in mesoporous metal–organic frameworks MIL-101 as an efficient and recyclable catalyst for the asymmetric hydrogenation of α-ketoesters
2013
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.
1994
Viral dynamics in human immunodeficiency virus type 1 infection
1995 StandoutNature
Cyclizations of N-Acyliminium Ions
2004 Standout
The Combinatorial Synthesis of Bicyclic Privileged Structures or Privileged Substructures
2003 Standout
Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease.
1995
A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells.
1993 StandoutNobel
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Unusual Amino Acids in Medicinal Chemistry
2016
Structure-based drug design of nonpeptidic P2 substituents for HIV-1 protease inhibitors
1995
Construction of Enantiopure Pyrrolidine Ring System via Asymmetric [3+2]-Cycloaddition of Azomethine Ylides
2006 Standout
Synthesis of bridged bicyclic hydrazines via cyclic N-acylhydrazonium intermediates
1990
Catalytic Asymmetric Intramolecular [4+2] Cycloaddition of In Situ Generated ortho‐Quinone Methides
2017 StandoutNobel
Proteases and protease inhibitors in infectious diseases
2017
Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia
1997 StandoutScience
Calculation of Relative Binding Free Energies of Peptidic Inhibitors to HIV-1 Protease and Its I84V Mutant
1998
Inhibitors of human immunodeficiency virus integrase.
1993 StandoutNobel
Transition Metal-Catalyzed C–H Amination: Scope, Mechanism, and Applications
2017 Standout
Asymmetric synthesis of cis- and trans-γ-lactones useful in HIV-1 protease inhibitor synthesis
1994
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
1997 StandoutScience
DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein
1994
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Cu-Catalyzed Azide−Alkyne Cycloaddition
2008 StandoutNobel
Nonpeptide HIV protease inhibitors designed to replace a bound water
1993
Biosynthetic and Biomimetic Electrocyclizations
2005
Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma.
1995 StandoutNobel
Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex.
1990
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
2002 Standout
Recent developments in the design of angiotensin‐converting enzyme inhibitors
1985
Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease
1997
Works of Sally Redshaw being referenced
Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere
1991
Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production in vivo
2006
Rational Design of Peptide-Based HIV Proteinase Inhibitors
1990 Science
The design and synthesis of the Angiotensin Converting Enzyme inhibitor Cilazapril and related bicyclic compounds
1986
Synthesis of (±)-eriobrucinol and regioisomeric monoterpenoid coumarins, using intramolecular cycloadditions
1983
New potent inhibitors of angiotensin converting enzyme
1984
ChemInform Abstract: Studies Toward the Large‐Scale Synthesis of the HIV Proteinase Inhibitor Ro 31‐8959.
1994
Synthesis and structure of eriobrucinol and isomeric ‘cyclol’ meroterpenes
1979